Mylan's Role in the Fight Against COVID-19
As a leading global pharmaceutical company, Mylan is committed to continue doing its part in support of public health needs amid the evolving COVID-19 pandemic. The company’s priorities remain protecting the health and safety of our workforce, continuing to produce critically needed medicines, deploying our resources and expertise in the fight against COVID-19 through potential prevention and treatment efforts, and supporting the communities in which we operate.
>7,500
Products Across 10 Therapeutic Categories
69
Products on WHO List of Prequalified Products
Manufactured ~5 Billion
ARV Tablets and Capsules
12
Global
R&D Centers
of the ~23.3M HIV+ Patients on Treatment Depend on one of our Products
of the World’s HIV+ Children on Treatment Depend on one of our Products
- The Council of Scientific & Industrial Research (CSIR) and Mylan Announce Partnership to Advance Therapeutic Options for Management of COVID – 19
- Mylan Initiates Supply of Remdesivir in India, Under Brand Name DESREM™
- Mylan Secures Regulatory Approval for Remdesivir Lyophilized Powder for Injection 100 mg/vial in India for Restricted Emergency Use in COVID-19 Patients
- Mylan Provides Medical Equipment to Establish COVID-19 care center in Hosur, India
- Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19